Atomo Diagnostics (AT1) 2022年年度报告「ASX」.pdf

1、ATOMO DIAGNOSTICS LIMITED ACN 142 925 684ATOMODIAGNOSTICS.COMAnnual Report 20221We are a global company.From our research,development and corporate office in Sydney,Australia;with production capabilities in the U.S.A.and manufacture and distribution in South Africa we are Atomo.Atomo Corporate Video

2、 2022CONTENTS ATOMO ANNUAL REPORT FY2201 FY22 AT A GLANCE 202 CHAIRMANS LETTER 303 CEO REPORT 504 KEY ACHIEVEMENTS AND CHALLENGES FY22 705 DELIVERING ON OUR STRATEGY WITH UNIQUE TECHNOLOGY AND KNOWLEDGE 806 WHAT WE VALUE,HOW WE CONTRIBUTE 1007 STRATEGY FOR FY23 AND BEYOND 1308 DIRECTORS REPORT 1609

3、FINANCIAL STATEMENTS 38 Statement of Profit or Loss and Other Comprehensive Income 41 Statement of Financial Position 42 Statement of Changes in Equity 43 Statement of Cash Flows 4410 NOTES TO FINANCIAL STATEMENTS 4511 DIRECTORS DECLARATION 7812 INDEPENDENT AUDITORS REPORT 8013 SHAREHOLDER INFORMATI

4、ON 8414 CORPORATE DIRECTORY 88201 FY22 AT A GLANCE302 CHAIRMANS LETTERDear Shareholders,I write to you as we see signs of the COVID-19 pandemic easing and realise the benefits of the widespread adoption of rapid testing.The communitys everyday experiences of the pandemic include the widespread adopt

5、ion of rapid testing in the workplace and at home,in addition to established clinical settings.The benefits of frequent and convenient screening relieve demands on centralised testing resources.The growing popularity of rapid testing reflects people exercising a greater level of control over their h

6、ealth.Self-testing allows individuals to accurately assess and act,based on their condition.It is against this transformed landscape that I am pleased to introduce Atomo Diagnostics Annual Report for the 2022 Financial Year.OUR BUSINESSAtomo supplies devices and screening tests for the rapid testing